1. A new opportunity for nanomedicines: Micellar cytochrome P450 inhibitors to improve drug efficacy in a cancer therapy model 
Marion Paolini, Laurence Poul, PhD, Audrey Darmon, Matthieu Germain, PhD, Agnès Pottier, PhD, Laurent Levy, PhD, Eric Vibert, MD, PhD 
Nanomedicine: Nanotechnology, Biology and Medicine 
Volume 13, Issue 5, Pages (July 2017)
DOI: /j.nano
Copyright © 2017 NANOBIOTIX Terms and Conditions

2. Figure 1
Relative concentration of (A) docetaxel and (B) pooled docetaxel's metabolites M1+M3 detected by LC/MS/MS analysis after 6-h incubation on human recombinant CYP3A4 enzymes. Bars are the mean of three independent experiments (points shown on the figure), each normalized on the reference value before averaging. Values were set to zero when <LOQ (A) reference value: docetaxel concentration in sample blank (B) reference value: M1+M3 concentration in sample “no inhibitor”.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2017 NANOBIOTIX Terms and Conditions

3. Figure 2
Relative concentration of pooled docetaxel's metabolites M1+M3 detected by LC/MS/MS analysis after 6-h incubation on human HepaRG cells. Bars are the mean of two independent experiments (points shown on the figure), each normalized on the reference value sample “no inhibitor” before averaging. Values were set to zero when <LOQ.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2017 NANOBIOTIX Terms and Conditions

4. Figure 3
Antitumor efficacy study on HT-29 comparing DHB-micelles and docetaxel–micelles versus docetaxel–micelles alone. Filled black diamonds: NaCl 0.9% IV injected on days 0, 1, 2, 5, 8 and 9 (3 mice); filled gray triangles: Docetaxel 10mg/kg IV injected on days 1, 5, 9 (5 mice); gray cross: DHB-micelles 5mg/kg IV injected on days 0, 2, and 8 and docetaxel 10mg/kg IV injected on days 1, 5 and 9 (5 mice). (A) Mean tumor volume (± S.E.M.) (B) Kaplan–Meier diagram. Arrows: injections (gray arrow DHB-micelles injection and black arrow docetaxel injection).
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2017 NANOBIOTIX Terms and Conditions

5. Figure 4
Antitumor efficacy study on MDA-MB-231 comparing DHB-micelles and docetaxel–micelles versus docetaxel–micelles alone. Filled black diamonds: NaCl 0.9% IV injected on days 0, 1, 4, 5, 8 and 9 (6 mice); filled gray squares: Docetaxel 10mg/kg IV injected on days 1, 5, 9 (8 mice); filled gray triangles: DHB-micelles 13.3mg/kg IV injected on days 0, 4, and 8 and docetaxel 10mg/kg IV injected on day 1, 5 and 9 (8 mice); gray cross: docetaxel 15mg/kg IV injected on days 1, 5, 9 (8 mice). (A) Mean tumor volume (± S.E.M.) (B) Kaplan–Meier diagram. Arrows: injections (gray arrow DHB micelles injection and black arrow docetaxel injection).
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2017 NANOBIOTIX Terms and Conditions

6. Figure 5
Docetaxel concentration in MDA-MB-231 tumors comparing DHB-micelles and docetaxel–micelles versus docetaxel–micelles alone. Filled triangles: NaCl 0.9% IV injected; filled circles: DHB-micelles 13.3mg/kg IV injected. NaCl 0.9% and DHB-micelles were injected 24h prior to docetaxel 10mg/kg. Results are the mean of docetaxel concentrations in tumors (three tumors per timepoint)±S.E.M.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2017 NANOBIOTIX Terms and Conditions

7. Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2017 NANOBIOTIX Terms and Conditions